Novozymes reported mixed Q4 22 earnings, as the top-line beat was offset by an earnings miss. Organic growth of 11% was attributable to broad-based growth even as profitability missed expectations on account of raw material headwinds. Importantly, growth in Household and Food, Beverages & Human Health bounced back strongly.
FY23 revenue growth is expected to come in at 4-7% with the adjusted EBIT margin at 25-26%. We will trim our estimates, to factor in the softer than expected margin guidanc ....
30 Jan 2023
Q4 22: solid top-line momentum even as profits fall short
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q4 22: solid top-line momentum even as profits fall short
- Published:
30 Jan 2023 -
Author:
Virendra Chauhan -
Pages:
3
Novozymes reported mixed Q4 22 earnings, as the top-line beat was offset by an earnings miss. Organic growth of 11% was attributable to broad-based growth even as profitability missed expectations on account of raw material headwinds. Importantly, growth in Household and Food, Beverages & Human Health bounced back strongly.
FY23 revenue growth is expected to come in at 4-7% with the adjusted EBIT margin at 25-26%. We will trim our estimates, to factor in the softer than expected margin guidanc ....